Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
10 hedge funds and large institutions have $604K invested in Evoke Pharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0% more funds holding
Funds holding: 10 → 10 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
2.06% less ownership
Funds ownership: 17.6% → 15.54% (-2.1%)
11% less capital invested
Capital invested by funds: $678K → $604K (-$74.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.11K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$866 |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$35.3K |
| 2 |
BRF
B. Riley Financial
Los Angeles,
California
|
-$12.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NCM
1
Nantahala Capital Management
New Canaan,
Connecticut
| $385K | – | – | – |
|
|
BL
2
Bleichroeder LP
New York
| $179K | – | – | – |
|
|
3
Citadel Advisors
Miami,
Florida
| $33K | -$35.3K | -12,261 | -49% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $5.17K | +$5.11K | +1,775 | +833% |
|
|
5
Fidelity Investments
Boston,
Massachusetts
| $792 | +$866 | +301 | New |
|
6
BlackRock
New York
| $317 | – | – | – |
|
|
SS
7
SBI Securities
Tokyo,
Japan
| $195 | – | – | – |
|
8
Morgan Stanley
New York
| $166 | – | – | – |
|
|
NA
9
NewEdge Advisors
New Orleans,
Louisiana
| $44 | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| $26 | +$3 | +1 | +11% |
|
|
BRF
11
B. Riley Financial
Los Angeles,
California
| – | -$12.2K | -20,000 | Closed |
|
EVOK Hedge Fund Activity: Q2 2025 in Review
10 of the 7,603 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q2 2025, worth a combined $604K — down 11% from $678K a quarter earlier.
Fund positioning in EVOK was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 2 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.11K. The largest seller was Citadel Advisors, cutting an estimated $35.3K.
- 10 institutional investors held Evoke Pharma (EVOK) as of Q2 2025, unchanged from Q1 2025.
- Funds reported $604K of Evoke Pharma stock for Q2 2025, down 11% quarter-over-quarter.
- 1 fund opened new Evoke Pharma positions in Q2 2025 and 1 closed out, a net change of 0 holders.
- The largest Evoke Pharma buyer in Q2 2025 was Tower Research Capital (TRC), an estimated $5.11K added.
- The largest Evoke Pharma seller in Q2 2025 was Citadel Advisors, an estimated $35.3K sold.
Based on aggregated 13F filings for Q2 2025.